Quick Links: Consensus Ratings,
Ratings History,
Earnings History,
Company Description
Consensus Ratings for ICON plc (NASDAQ:ICLR) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | 1 Hold Rating(s), 6 Buy Rating(s), 1 Strong Buy Rating(s) |
| Consensus Rating: | Buy |
| Consensus Price Target: | $35.08 (5.07% upside) |
Analysts' Ratings History for ICON plc (NASDAQ:ICLR)| Date | Firm | Action | Company | Old Rating | New Rating | Old Price Target | New Price Target | Details |
|---|
| 4/25/2013 | ISI Group | Boost Price Target | ICON plc (ICLR) | | Buy | $36.50 | $37.50 | View |
| 3/12/2013 | Jefferies Group | Boost Price Target | ICON plc (ICLR) | | Buy | $33.50 | $38.00 | View |
| 2/21/2013 | Jefferies Group | Boost Price Target | ICON plc (ICLR) | | Buy | $32.00 | $33.50 | View |
| 2/20/2013 | ISI Group | Reiterated Rating | ICON plc (ICLR) | | Buy | $32.00 | $33.00 | View |
| 2/20/2013 | Robert W. Baird | Reiterated Rating | ICON plc (ICLR) | | Outperform | | $39.00 | View |
| 2/20/2013 | Raymond James | Upgrade | ICON plc (ICLR) | Market Perform | Strong-Buy | $20.00 | $37.00 | View |
| 2/15/2013 | Barclays Capital | Boost Price Target | ICON plc (ICLR) | | Overweight | $29.00 | $34.00 | View |
| 2/15/2013 | Wells Fargo | Reiterated Rating | ICON plc (ICLR) | | Outperform | | | View |
| 2/4/2013 | Jefferies Group | Reiterated Rating | ICON plc (ICLR) | | Buy | | $32.00 | View |
| 1/14/2013 | Sterne Agee | Reiterated Rating | ICON plc (ICLR) | | Neutral | $24.00 | $25.00 | View |
| 1/11/2013 | Barclays Capital | Boost Price Target | ICON plc (ICLR) | | Overweight | $27.00 | $29.00 | View |
| 1/11/2013 | Robert W. Baird | Reiterated Rating | ICON plc (ICLR) | | Outperform | $34.00 | $32.00 | View |
| 12/5/2012 | Jefferies Group | Boost Price Target | ICON plc (ICLR) | | Buy | $29.00 | $32.00 | View |
| 12/5/2012 | Raymond James | Downgrade | ICON plc (ICLR) | Outperform | Market Perform | | $27.00 | View |
| 11/16/2012 | Wells Fargo | Reiterated Rating | ICON plc (ICLR) | | Outperform | | | View |
| 11/2/2012 | Robert W. Baird | Upgrade | ICON plc (ICLR) | Neutral | Outperform | $25.00 | $30.00 | View |
| 9/10/2012 | Sterne Agee | Downgrade | ICON plc (ICLR) | Buy | Neutral | | $26.00 | View |
| 9/10/2012 | Jefferies Group | Upgrade | ICON plc (ICLR) | Hold | Buy | $24.00 | $29.00 | View |
| 7/9/2012 | ISI Group | Initiated Coverage | ICON plc (ICLR) | | Overweight | | $26.00 | View |
| 6/18/2012 | William Blair | Upgrade | ICON plc (ICLR) | Market Perform | Outperform | | | View |
| 5/18/2012 | Lazard Capital Markets | Upgrade | ICON plc (ICLR) | Neutral | Buy | | | View |
| 4/25/2012 | Jefferies Group | Boost Price Target | ICON plc (ICLR) | | Hold | $18.50 | $24.00 | View |
| 4/25/2012 | Wells Fargo | Upgrade | ICON plc (ICLR) | Market Perform | Outperform | | | View |
| 4/24/2012 | Sterne Agee | Upgrade | ICON plc (ICLR) | Neutral | Buy | | | View |
| 2/18/2012 | Jefferies Group | Boost Price Target | ICON plc (ICLR) | | | | $18.50 | View |
| 2/17/2012 | Jefferies Group | Reiterated Rating | ICON plc (ICLR) | | Hold | | | View |
| 2/15/2012 | Sterne Agee | Upgrade | ICON plc (ICLR) | Underperform | Neutral | | | View |
| 2/9/2012 | Zacks | Upgrade | ICON plc (ICLR) | Underperform | Neutral | | | View |
| 1/11/2012 | Zacks | Downgrade | ICON plc (ICLR) | Neutral | Underperform | | | View |
| 1/3/2012 | Deutsche Bank | Downgrade | ICON plc (ICLR) | | Hold | | | View |
| 1/3/2012 | Deutsche Bank | Downgrade | ICON plc (ICLR) | Buy | Hold | $20.50 | $18.50 | View |
| 12/13/2011 | Zacks | Upgrade | ICON plc (ICLR) | Underperform | Neutral | | | View |
| 11/15/2011 | Sterne Agee | Initiated Coverage | ICON plc (ICLR) | | Underperform | | $18.50 | View |
| 11/2/2011 | Zacks | Downgrade | ICON plc (ICLR) | Neutral | Underperform | | | View |
| 10/10/2011 | JPMorgan Chase | Downgrade | ICON plc (ICLR) | | Neutral | | $18.00 | View |
| 9/8/2011 | Lazard Capital Markets | Downgrade | ICON plc (ICLR) | Buy | Neutral | | | View |
| 8/24/2011 | BB&T | Initiated Coverage | ICON plc (ICLR) | | Hold | | | View |
| 7/21/2011 | Jefferies Group | Downgrade | ICON plc (ICLR) | Buy | Hold | $21.50 | $28.00 | View |
| 1/17/2011 | Zacks | Upgrade | ICON plc (ICLR) | Underperform | Neutral | | | View |
| 4/14/2011 | Zacks | Reiterated Rating | ICON plc (ICLR) | Underperform | Underperform | | | View |
| 2/28/2011 | Zacks | Downgrade | ICON plc (ICLR) | Neutral | Underperform | | | View |
| 2/24/2011 | Standpoint Research | Downgrade | ICON plc (ICLR) | Buy | Hold | | | View |
| 1/12/2011 | Zacks | Upgrade | ICON plc (ICLR) | Underperform | Neutral | | | View |
| 1/4/2011 | Zacks | Upgrade | ICON plc (ICLR) | Underperform | Neutral | | | View |
| 12/31/2010 | Zacks | Downgrade | ICON plc (ICLR) | Neutral | Underperform | | | View |
| 12/16/2010 | Zacks | Downgrade | ICON plc (ICLR) | Neutral | Underperform | | | View |
Click Here to view only the most recent ratings from each analyst for this stock.
Earnings History for ICON plc (NASDAQ:ICLR)
About ICON plc
ICON public limited company (ICON) is a contract research organization (CRO), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs, which support all stages of the clinical development process, which include from compound selection to Phase I-IV clinical studies. On February 28, 2012 the Company acquired PriceSpective LLC (PriceSpective). On February 15, 2012, the Company acquired BeijingWits Medical Limited (BeijingWits). On July 14, 2011, the Company acquired Firecrest Clinical Limited (Firecrest Clinical), a market provider of technology solutions, which boost investigator site performance and study management. In February 2013, Cross Country Healthcare Inc announced the sale of its clinical trial services business to the Company.